Physician profile
Sean Fedyna
NPI 1497071518
$914.81
in general payments reported to CMS, 2019-2025
11 companies · $292 in 2025
The $292 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $55.84 · 2023: $287 · 2024: $280 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $858.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $519.52 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $89.76 | 2022-2024 | Tezspire, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.65 | 2022-2023 | Stiolto Respimat, Spiriva Respimat |
| Mylan Specialty L.P. | $43.45 | 2022-2023 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $42.53 | 2023-2025 | Dupixent |
| Genzyme Corporation | $33.23 | 2023 | |
| Amgen INC. | $33.15 | 2025 | Tezspire |
| Tempus Ai, INC | $28.78 | 2024 | |
| Axsome Therapeutics, INC. | $20.93 | 2024 | Sunosi |
| Merck Sharp & Dohme LLC | $16.45 | 2023 | |
| Insmed, INC. | $16.36 | 2023 | Arikayce |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Fedyna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.